2025-08-20 - Analysis Report
Okay, here's a report analyzing TG Therapeutics Inc. (TGTX) based on the provided data.

## TG Therapeutics Inc. (TGTX) Analysis Report

**Company Overview:** TG Therapeutics Inc. is a biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.

### 1. Performance vs. S&P 500 (VOO)

*   **TGTX Cumulative Return:** 48.60%
*   **VOO Cumulative Return:** 100.85%
*   **Absolute Deviation:** -30.5 (TGTX underperformed VOO by 30.5%)
*   **Relative Deviation:** 11.4 (Current deviation is positioned in the 11.4th percentile of its historical deviation range relative to VOO)

**Analysis:** TGTX has significantly underperformed the S&P 500 (VOO) over the analyzed period. The relative deviation suggests that this underperformance, while substantial, is not at the extreme end of its historical range.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD    | Alpha   | Beta   | Cap(B) |
| :----------- | :------ | :------ | :------ | :----- | :------ |
| 2015-2017  | -6.0%   | 56.5%   | -35.0%  | -0.1  | 1.3   |
| 2016-2018  | -8.0%   | 58.6%   | -26.0%  | 0.0   | 0.7   |
| 2017-2019  | 74.0%   | 58.6%   | 44.0%   | 0.0   | 1.8   |
| 2018-2020  | 402.0%  | 58.6%   | 382.0%  | -0.4  | 8.3   |
| 2019-2021  | 125.0%  | 63.5%   | 76.0%   | -0.5  | 3.0   |
| 2020-2022  | -76.0%  | 70.4%   | -78.0%  | -0.6  | 1.9   |
| 2021-2023  | -350.0% | 70.4%   | -368.0% | -0.8  | 2.7   |
| 2022-2024  | 71.0%   | 73.1%   | 45.0%   | -0.9  | 4.8   |
| 2023-2025  | 55.0%   | 73.1%   | 3.0%   | 0.4  | 4.4   |

**Analysis:**

*   **Volatility:** The stock exhibits significant volatility, as evidenced by the high Maximum Drawdown (MDD) values.
*   **Alpha:** Alpha values vary significantly across different periods, indicating periods of both outperformance and underperformance relative to its benchmark. The negative alpha in recent years suggests considerable underperformance.
*   **Beta:** Beta values fluctuate around 0, indicating that the stock's price movement is not strongly correlated with the overall market.

### 2. Recent Price Action

*   **Current Price:** 27.73
*   **Last Market Data:** {'price': 27.92, 'previousClose': 27.73, 'change': 0.69} (Price Increased)
*   **5-day Moving Average:** 27.71
*   **20-day Moving Average:** 31.54
*   **60-day Moving Average:** 35.12

**Analysis:** The current price is below the 20-day and 60-day moving averages, suggesting a short-term downtrend. The price did increase in the last market data. The 5-day moving average is almost the same as the current price.

### 3. Technical Indicators

*   **Market Risk Indicator (MRI):** 0.329 (Low Risk)
*   **RSI:** 21.73 (Oversold)
*   **PPO:** -0.98
*   **Hybrid Signal:** Cash 64%, Sell 9.1% of holdings (206 shares - Caution - MRI: 0.33)
*   **Recent Relative Deviation Change (20-day):** -0.6 (Short-term decrease)
*   **Expected Return:** -223.7% (Expected underperformance relative to the S&P 500 over a 2+ year investment horizon)

**Analysis:**

*   The RSI indicates that the stock is currently oversold, which could signal a potential buying opportunity for some investors.
*   PPO is negative, indicating a downtrend.
*   The Hybrid Signal suggests caution, recommending a high cash position and a small reduction in holdings.
*   The significant negative expected return highlights the potential for continued underperformance compared to the S&P 500.
*   The price increase in the Last Market data({'price': 27.92, 'previousClose': 27.73, 'change': 0.69}) may reflect a minor positive reaction, but needs to be observed in context with other factors.

### 4. Recent News & Significant Events

*   **2025-08-16:** Major business developments, regulatory changes, or market events.
*   **2025-08-18:** Analyst discussions on performance, industry trends, and global economic factors.
*   **2025-08-19:** Notable stock volatility due to recent news, earnings reports, or executive actions.
*   **2025-08-17:** Market experts highlight both risks and opportunities, advising monitoring of news and announcements.

**Analysis:** Recent news and analyst commentary point to ongoing volatility and potential catalysts influencing TG Therapeutics' stock price. Investors should closely monitor news releases and company announcements.

### 5. Recent Earnings Analysis

| Date       | EPS  | Revenue     |
| :--------- | :--- | :---------- |
| 2025-08-08 | 0.19 | 0.14 B\$ |
| 2025-05-09 | 0.03 | 0.12 B\$ |
| 2024-11-07 | 0.03 | 0.08 B\$ |
| 2024-08-09 | 0.05 | 0.07 B\$ |
| 2025-08-08 | 0.05 | 0.07 B\$ |

**Analysis:**

*   Recent EPS figures show some variability, with the latest quarter (2025-08-08) showing a higher EPS of 0.19.
*   Revenue has generally been increasing over the analyzed period, with the latest quarter showing the highest revenue of 0.14 B\$.

### 6. Financial Information:

**Revenue and Profitability:**

| Quarter      | Revenue  | Profit Margin |
| :----------- | :------- | :------------ |
| 2025-06-30 | \$0.14B  | 86.58%        |
| 2025-03-31 | \$0.12B  | 87.14%        |
| 2024-12-31 | \$0.11B  | 85.77%        |
| 2024-09-30 | \$0.08B  | 88.86%        |
| 2024-06-30 | \$0.07B  | 88.70%        |

**Capital and Profitability:**

| Quarter      | Equity   | ROE       |
| :----------- | :-------- | :-------- |
| 2025-06-30 | \$0.28B  | 10.20%   |
| 2025-03-31 | \$0.24B  | 2.13%    |
| 2024-12-31 | \$0.22B  | 10.49%   |
| 2024-09-30 | \$0.19B  | 2.02%    |
| 2024-06-30 | \$0.18B  | 3.87%    |

**Analysis:**

*   **Revenue:** The company has shown consistent revenue growth over the past several quarters.
*   **Profit Margin:** Profit margins are consistently high, indicating strong operational efficiency.
*   **Equity:** The company's equity has increased over the past several quarters, suggesting healthy capital accumulation.
*   **ROE:** Return on Equity (ROE) has fluctuated, but the latest quarter shows a significant increase.

### 7. Overall Analysis and Conclusion

TG Therapeutics Inc. presents a mixed picture.  While revenue and profit margins are strong, the stock has significantly underperformed the S&P 500. Recent news suggests volatility and the technical indicators point to an oversold condition with a negative short-term outlook and significant expected underperformance.

**Key Considerations:**

*   **Underperformance:** The substantial underperformance relative to the S&P 500 is a major concern.
*   **Volatility:** High volatility, as indicated by MDD, suggests a higher risk profile.
*   **Oversold Condition:** The oversold RSI could present a short-term trading opportunity, but should be considered in conjunction with other factors.
*   **Recent News:** Keep a close eye on company announcements and news related to regulatory changes, market events, and business developments, as they can significantly impact the stock.
*   **Positive Financials:** Recent improvements in revenue and profit margins are positive signals for the companyâ€™s operational health.
*   **Hybrid Signal: Cash Position:** the cash position recommends to take cautious position

**Recommendation:** Given the underperformance, volatility, and negative outlook, a cautious approach is warranted. Investors should carefully weigh the risks and potential rewards before making any investment decisions. Monitoring upcoming news and earnings releases will be crucial.
